In vivo production of engineered ACE2 decoy protects lungs from SARS-CoV-2 infection

In vivo production of engineered ACE2 decoy protects lungs from SARS-CoV-2 infection

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants repeatedly evade the immune system within short periods. Thus, next-generation therapeutics that are resistant to mutations and can be rapidly supplied to individuals in an emergency are required. Here, we designed an mRNA encodin...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuta Suzuki, Takayuki Miyazaki, Yoko Ida, Tatsuya Suzuki, Yumi Itoh, Shuto Nakao, Keita Kondo, Kenji Kubara, Keisuke Nishioka, Hiroki Muto, Ryuji Watari, Toshifumi Hirayama, Dai Kakiuchi, Shinya Sato, Satoshi Inoue, Yoshifumi Uemoto, Yohei Mukai, Atsushi Hoshino, Toru Okamoto, Junji Matsui
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
MT: Oligonucleotides: Therapies and Applications
mRNA therapeutics
mRNA delivery
ACE2 decoy
escape mutation
lipid nanoparticles
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253125000216
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items